Matthias Schwab

Latest

Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo
Structural variation of the coding and non-coding human pharmacogenome
Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
Cross-ancestry GWAS defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations
Challenges and opportunities associated with rare-variant pharmacogenomics
Pharmacogenomics in pediatric medicine and drug development
Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation
Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets
How to manage polypharmacia?
Pharmacogenetic diagnostics to improve drug therapy in clinical practice
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver.
α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin.
Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression.
The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center
A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort
Identification of Cardiomyopathy-Associated Circulating miRNA Biomarkers in Muscular Dystrophy Female Carriers Using a Complementary Cardiac Imaging and Plasma Profiling Approach
Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn’s Disease
Genetic variation in human drug-related genes.
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.